Venture Capital News | Private Equity News
Summary
However, to date, these external real-world data elements werent accessible to trial sponsors at scale, which is why were building the machinery and support required to change the paradigm, said Sam Roosz, co-founder and CEO of Crescendo Health. Sponsors can leverage Crescendo Healths model to support a variety of use cases, including: Health economics and outcomes research that reflects the whole patient journey, including the true costs of their care; Post-marketing observational studies or safety registries that reduce the burdens placed on sites and patients, while also reducing costs for sponsors; and Longer-term follow-up or observational extension studies that help researchers understand the impact of interventions over time. As more trials move to decentralized formats and competitive pressure builds to bring therapeutics to market faster and cheaper, Crescendo Health has an incredible opportunity to power a new era of clinical research. During its early-access period, Crescendo Health completed validation studies that demonstrated the effectiveness of its model in partnership with leading life science-organizations, including a top-three contract research organization that conducts thousands of clinical trials each year. Moving forward, Crescendo Health plans to scale its services throughout the life sciences industry and will use the investment to build software tools that will enable its clients to research the longitudinal effects of treatments and track outcomes over time.